Free Shipping on All Orders $75 Or More!

Your Trusted Brand for Over 35 Years

Health Protocols

Polycystic Ovary Syndrome (PCOS)

  1. Azziz R, Woods KS, Reyna R et al. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab. 2004 Jun;89(6):2745-9.
  2. Azziz R, Carmina E, Dewailly D, et al. Androgen Excess Society: Position statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab 2006, 91:4237-4245.
  3. Moran LJ, Misso ML, Wild RA, Norman RJ. Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2010 Jul-Aug;16(4):347-63.
  4. McCartney CR, Bellows AB, Gingrich MB, et al. Exaggerated 17-hydroxyprogesterone response to intravenous infusions of recombinant human LH in women with polycystic ovary syndrome. Am J Physiol Endocrinol Metab. 2004 Jun;286(6):E902-8.
  5. Diamanti-Kandarakis E et al. Pathophysiology and types of dyslipidemia in PCOS. Trends in Endocrinology & Metabolism. 2007 September;18(7):280–285.
  6. Sasaki A, Emi Y, Matsuda M et al. Increased arterial stiffness in mildly-hypertensive women with polycystic ovary syndrome. J Obstet Gynaecol Res. 2011 Feb 11. doi: 10.1111/j.1447-0756.2010.01375.x.
  7. Diamanti-Kandarakis E. Polycystic ovarian syndrome: pathophysiology, molecular aspects and clinical implications. Expert Reviews in Molecular Medicine 2008 10 e3 (Review).
  8. Drosdzol A, Skrzypulec V, Mazur B, Pawlińska-Chmara R. Quality of life and marital sexual satisfaction in women with polycystic ovary syndrome. Folia Histochem Cytobiol. 2007;45 Suppl1:S93-7.
  9. Teede H, Deeks A, Moran L. Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Med. 2010 Jun 30;8:41.
  10. Chittenden BG, Fullerton G, Maheshwari A, Bhattacharya S. Polycystic ovary syndrome and the risk of gynaecological cancer: a systematic review. Reprod Biomed Online. 2009 Sep;19(3):398-405.
  11. Pasquali R, Stener-Victorin E, Yildiz BO, et al. PCOS Forum: research in polycystic ovary syndrome today and tomorrow. Clin Endocrinol (Oxf). 2011 Apr;74(4):424-433.
  12. Ma YM, Li R, Qiao J, Characteristics of abnormal menstrual cycle and polycystic ovary syndrome in community and hospital populations. Chin Med J (Engl). 2010 Aug;123(16):2185-9.
  13. Lowenstein EJ. Diagnosis and management of the dermatologic manifestations of the polycystic ovary syndrome. Dermatol Ther. 2006 Jul-Aug;19(4):210-23.
  14. Azziz R. PCOS: a diagnostic challenge. Reprod Biomed Online. 2004 Jun;8(6):644-8.
  15. van der Spuy ZM, Dyer SJ. The pathogenesis of infertility and early pregnancy loss in polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol. 2004 Oct;18(5):755-71.
  16. Martínez-Bermejo E, Luque-Ramírez M, Escobar-Morreale HF. Obesity and the polycystic ovary syndrome. Minerva Endocrinol. 2007 Sep;32(3):129-40.
  17. Faloia E, Canibus P, Gatti C, Frezza F, Santangelo M, Garrapa GG, Boscaro M. Body composition, fat distribution and metabolic characteristics in lean and obese women with polycystic ovary syndrome. J Endocrinol Invest. 2004 May;27(5):424-9.
  18. Pasquali R, Gambineri A.Insulin-sensitizing agents in polycystic ovary syndrome. Eur J Endocrinol. 2006 Jun;154(6):763-75.
  19. Pelusi B, Gambineri A, Pasquali R. Type 2 diabetes and the polycystic ovary syndrome. Minerva Ginecol. 2004 Feb;56(1):41-51.
  20. Higgins SP, Freemark M, Prose NS. Acanthosisnigricans: a practical approach to evaluation and management. Dermatol Online J. 2008 Sep 15;14(9):2.
  21. Artini PG, Di Berardino OM, Simi G, Best methods for identification and treatment of PCOS. Minerva Ginecol. 2010 Feb;62(1):33-48.
  22. Shi Y, Guo M, Yan J et al. Analysis of clinical characteristics in large-scale Chinese women with polycystic ovary syndrome. Neuro Endocrinol Lett. 2007 Dec;28(6):807-10.
  23. Chen MJ, Yang WS, Chen CL, et al. The relationship between anti-Mullerian hormone, androgen and insulin resistance on the number of antral follicles in women with polycystic ovary syndrome. Hum Reprod. 2008 Apr;23(4):952-7.
  24. Dewailly D, Pigny P, Soudan B, et al. Reconciling the definitions of polycystic ovary syndrome: the ovarian follicle number and serum anti-Müllerian hormone concentrations aggregate with the markers of hyperandrogenism. J Clin Endocrinol Metab. 2010 Sep;95(9):4399-405.
  25. van Houten EL, Themmen AP, Visser JA. Anti-Müllerian hormone (AMH): regulator and marker of ovarian function. Ann Endocrinol (Paris). 2010 May;71(3):191-7.
  26. Pellatt L, Rice S, Mason HD. Anti-Müllerian hormone and polycystic ovary syndrome: a mountain too high? Reproduction. 2010 May;139(5):825-33.
  27. Chang PL, Lindheim SR, Lowre C. Normal Ovulatory Women with Polycystic Ovaries Have Hyperandrogenic Pituitary-Ovarian Responses To Gonadotropin-Releasing Hormone-Agonist Testing. J Clin Endocrinol Metab. 2000; 85(3):995-1000
  28. Guzick DS. Polycystic ovary syndrome. Obstet Gynecol 2004;103:181-193.
  29. Tsilchorozidou T, Overton C, Conway GS. The pathophysiology of polycystic ovary syndrome. Clin Endocrinol (Oxf) 2004;60:1-17.
  30. Jakubowski L. [Genetic aspects of polycystic ovary syndrome]. Endokrynol Pol. 2005 May-Jun;56(3):285-93.
  31. Diamanti-Kandarakis, E, et al. The role of genes and environment in the etiology of PCOS. Endocrine. 2006 August;30(1):19-26.
  32. Bremer AA and Miller WL. The serine phosphorylation hypothesis of polycystic ovary syndrome: a unifying mechanism for hyperandrogenemia and insulin resistance. Fertil Steril. 2008 May;89(5):1039-48.
  33. Wood JR, Nelson VL, Ho C, et al. The molecular phenotype of polycystic ovary syndrome (PCOS) theca cells and new candidate PCOS genes defined by microarray analysis. J Biol Chem. 2003 Jul 18;278(29):26380-90.
  34. Villa J, Pratley RE. Adipose Tissue Dysfunction in Polycystic Ovary Syndrome. Curr Diab Rep. 2011 Mar 19. [Epub ahead of print]
  35. Witchel SF. Puberty and polycystic ovary syndrome. Mol Cell Endocrinol. 2006 Jul 25;254-255:146-53.
  36. Escobar-Morreale HF, Luque-Ramírez M, González F. Circulating inflammatory markers in polycystic ovary syndrome: a systematic review and meta analysis. Fertil Steril. 2011 Mar 1;95(3):1048-58.e1-2.
  37. Takeuchi T, Tsutsumi O, Ikezuki Y, Takai Y, Taketani Y. Positive relationship between androgen and the endocrine disruptor, bisphenol A, in normal women and women with ovarian dysfunction. Endocr J. 2004 Apr;51(2):165-9.
  38. Petríková J, Lazúrová I. Polycystic ovary syndrome and autoimmune diseases. Vnitr Lek. 2010 May;56(5):414-7.
  39. Hernández I, Parra A, Méndez I, et al. Hypothalamic dopaminergic tone and prolactin bioactivity in women with polycystic ovary syndrome. Arch Med Res. 2000 Mar-Apr;31(2):216-22.
  40. Schuring AN, Schulte N, Sonntag B, Kiesel L. Androgens and insulin--two key players in polycystic ovary syndrome. Recent concepts in the pathophysiology and genetics of polycystic ovary syndrome. Gynakol Geburtshilfliche Rundsch. 2008;48(1):9-15.
  41. Kopera D, Wehr E, Obermayer-Pietsch B. Endocrinology of hirsutism. Int J Trichology. 2010 Jan;2(1):30-5.
  42. Rathnayake D, Sinclair R. Use of spironolactone in dermatology. Skinmed. 2010 Nov-Dec;8(6):328-32; quiz 333.
  43. Polyzos NP, Tzioras S, Badawy AM, Valachis A, Dritsas C, Mauri D. Aromatase inhibitors for female infertility: a systematic review of the literature. Reprod Biomed Online. 2009 Oct;19(4):456-71.
  44. Fica S, Albu A, Constantin M, Dobri GA. Insulin resistance and fertility in polycystic ovary syndrome. J Med Life. 2008 Oct-Dec;1(4):415-22.
  45. Abu Hashim H, Shokeir T, Badawy A. Letrozole versus combined metformin and lomiphene citrate for ovulation induction in clomiphene-resistant women with polycystic ovary syndrome: a randomized controlled trial. Fertil Steril. 2010 Sep;94(4):1405-9.
  46. Nugent D, Vandekerckhove P, Hughes E, Arnot M, Lilford R. Gonadotrophin therapy for ovulation induction in subfertility associated with polycystic ovary syndrome. Cochrane Database Syst Rev. 2000;(4):CD000410.
  47. Mitwally MF, Casper RF. Use of an aromatase inhibitor for induction of ovulation in patients with an inadequate response to clomiphene citrate. Fertil Steril. 2001 Feb;75(2):305-9.
  48. Cianci A, De Leo V. Individualization of low-dose oral contraceptives. Pharmacological principles and practical indications for oral contraceptives. Minerva Ginecol. 2007 Aug;59(4):415-25.
  49. National Institute for Health and Clinical Excellence. 11 Clinical guideline 11: Fertility: assessment and treatment for people with fertility problems. London, 2004.
  50. Azziz R, Ehrmann D, Legro RS, et al. Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial. J Clin Endocrinol Metab. 2001 Apr;86(4):1626-32.
  51. Romualdi D, De Cicco S, Tagliaferri V, Proto C, Lanzone A, Guido M. The Metabolic Status Modulates the Effect of Metformin on the Antimullerian Hormone-Androgens-Insulin Interplay in Obese Women with Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2011 Feb 9. [Epub ahead of print]
  52. Yasmin E, Glanville J, Barth J, Balen AH. Effect of dose escalation of metformin on clinical features, insulin sensitivity and androgen profile in polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol. 2011 May;156(1):67-71. [Epub ahead of print]
  53. Grundy SM. Obesity, metabolic syndrome, and coronary atherosclerosis. Circulation. 2002;105(23):2696–2698.
  54. Harborne LR, Sattar N, Norman JE, Fleming R. Metformin and weight loss in obese women with polycystic ovary syndrome: comparison of doses. J Clin Endocrinol Metab. 2005;90(8):4593–4598.
  55. Glueck CJ, Wang P, Goldenberg N, Sieve-Smith L. Pregnancy outcomes among women with polycystic ovary syndrome treated with metformin. Hum Reprod. 2002;17(11):2858–2864.
  56. Tang T, Lord JM, Norman RJ et al. Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, d-chiro-inositol) for women with polycystic ovary syndrome, oligoamenorrhoea and subfertility. Cochrane Database Syst Rev. 2010;(1):CD003053. Doi: 10.1002/14651858.CD003053.
  57. Palomba S et al. Effects of metformin with or without supplementation with folate on homocysteine levels and vascular endothelium of women with polycystic ovary syndrome. Diabetes Care. 2010 Feb;33(2):246-51.
  58. Mastorakos G, Koliopoulos C, Deligeoroglou E et al. Effects of two forms of combined oral contraceptives on carbohydrate metabolism in adolescents with polycystic ovary syndrome. Fertility and Sterility. 2006 February; 85(2):420-427.
  59. Kiddy DS, et al. Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. Clin Endocrinol. 1992 January;36(1):105-11.
  60. Berrino F, et al. Reducing bioavailable sex hormones through a comprehensive change in diet: the diet and androgens (DIANA) randomized trial. Cancer Epidemiol Biomarkers Prev. 2001 January;10(1):25-33.
  61. Douglas CC, et al. Role of diet in the treatment of polycystic ovary syndrome. Fertil Steril. 2006 March; 85(3):679-88.
  62. Marsh K, et al. The optimal diet for women with polycystic ovary syndrome? Br J Nutr. 2005 August; 94(2):154-65.
  63. Sortino MA, Salomone S, Carruba MO, Drago F. Polycystic Ovary Syndrome: Insights into the Therapeutic Approach with Inositols. Frontiers in pharmacology. 2017;8:341.
  64. Muscogiuri G, Palomba S, Lagana AS, Orio F. Inositols in the Treatment of Insulin-Mediated Diseases. International journal of endocrinology. 2016;2016:3058393.
  65. Lagana AS, Rossetti P, Buscema M, La Vignera S, Condorelli RA, Gullo G, . . . Triolo O. Metabolism and Ovarian Function in PCOS Women: A Therapeutic Approach with Inositols. International journal of endocrinology. 2016;2016:6306410.
  66. Unfer V, Nestler JE, Kamenov ZA, Prapas N, Facchinetti F. Effects of Inositol(s) in Women with PCOS: A Systematic Review of Randomized Controlled Trials. International journal of endocrinology. 2016;2016:1849162.
  67. Genazzani AD, Lanzoni C, Ricchieri F, Jasonni VM. Myo-inositol administration positively affects hyperinsulinemia and hormonal parameters in overweight patients with polycystic ovary syndrome. Gynecol Endocrinol. 2008 Mar;24(3):139-44.
  68. Costantino D et al. Metabolic and hormonal effects of myo-inositol in women with polycystic ovary syndrome: a double-blind trial. Eur Rev Med Pharmacol Sci. 2009 Mar-Apr;13(2):105-10.
  69. Papaleo E et al. Myo-inositol in patients with polycystic ovary syndrome: a novel method for ovulation induction. Gynecol Endocrinol. 2007 Dec;23(12):700-3.
  70. Genazzani AD, Prati A, Santagni S, Ricchieri F, Chierchia E, Rattighieri E, . . . Artini PG. Differential insulin response to myo-inositol administration in obese polycystic ovary syndrome patients. Gynecological endocrinology: the official journal of the International Society of Gynecological Endocrinology. Dec 2012;28(12):969-973.
  71. Papaleo E, Unfer V, Baillargeon JP, Fusi F, Occhi F, De Santis L. Myo-inositol may improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial. Fertility and sterility. May 2009;91(5):1750-1754.
  72. Ciotta L, Stracquadanio M, Pagano I, Carbonaro A, Palumbo M, Gulino F. Effects of myo-inositol supplementation on oocyte's quality in PCOS patients: a double blind trial. European review for medical and pharmacological sciences. May 2011;15(5):509-514.
  73. Unfer V, Carlomagno G, Rizzo P, Raffone E, Roseff S. Myo-inositol rather than D-chiro-inositol is able to improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial. European review for medical and pharmacological sciences. Apr 2011;15(4):452-457.
  74. Kamenov Z, Kolarov G, Gateva A, Carlomagno G, Genazzani AD. Ovulation induction with myo-inositol alone and in combination with clomiphene citrate in polycystic ovarian syndrome patients with insulin resistance. Gynecological endocrinology: the official journal of the International Society of Gynecological Endocrinology. Feb 2015;31(2):131-135.
  75. Raffone E, Rizzo P, Benedetto V. Insulin sensitiser agents alone and in co-treatment with r-FSH for ovulation induction in PCOS women. Gynecological endocrinology: the official journal of the International Society of Gynecological Endocrinology. Apr 2010;26(4):275-280.
  76. Artini PG, Di Berardino OM, Papini F, Genazzani AD, Simi G, Ruggiero M, Cela V. Endocrine and clinical effects of myo-inositol administration in polycystic ovary syndrome. A randomized study. Gynecological endocrinology: the official journal of the International Society of Gynecological Endocrinology. Apr 2013;29(4):375-379.
  77. Gerli S et al. Randomized, double blind placebo-controlled trial: effects of myo-inositol on ovarian function and metabolic factors in women with PCOS. Eur Rev Med Pharmacol Sci. 2007 Sep-Oct;11(5):347-54.
  78. Zacchè MM, Caputo L, Filippis S, et al. Efficacy of myo-inositol in the treatment of cutaneous disorders in young women with polycystic ovary syndrome. Gynecol Endocrinol. 2009 Aug;25(8):508-13.
  79. Cheang KI, Baillargeon JP, Essah PA, et al. Insulin-stimulated release of D-chiro-inositol-containing inositolphosphoglycan mediator correlates with insulin sensitivity in women with polycystic ovary syndrome. Metabolism. 2008 Oct;57(10):1390-7.
  80. Baillargeon JP, Iuorno MJ, Jakubowicz DJ, et al. Metformin therapy increases insulin-stimulated release of D-chiro-inositol-containing inositolphosphoglycan mediator in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2004 Jan;89(1):242-9.
  81. Gupta A, Jakubowicz D, Nestler JE. Pioglitazone Therapy Increases Insulin-Stimulated Release of d-Chiro-Inositol-Containing Inositolphosphoglycan Mediator in Women with Polycystic Ovary Syndrome. Metabolic syndrome and related disorders. Oct 2016;14(8):391-396.
  82. Baillargeon JP, Iuorno MJ, Apridonidze T, Nestler JE. Uncoupling between insulin and release of a D-chiro-inositol-containing inositolphosphoglycan mediator of insulin action in obese women with polycystic ovary syndrome. Metab Syndr Relat Disord. 2010 Apr;8(2):127-36.
  83. Cheang KI, Sistrun SN, Morel KS, Nestler JE. Effect on Insulin-Stimulated Release of D-Chiro-Inositol-Containing Inositolphosphoglycan Mediator during Weight Loss in Obese Women with and without Polycystic Ovary Syndrome. International journal of endocrinology. 2016;2016:7631804.
  84. Bevilacqua A, Bizzarri M. Physiological role and clinical utility of inositols in polycystic ovary syndrome. Best practice & research. Clinical obstetrics & gynaecology. Nov 2016;37:129-139.
  85. Nestler JE et al. Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome. N Engl J Med. 1999 Apr 29;340(17):1314-20.
  86. Iuorno MJ, Jakubowicz DJ, Baillargeon JP, Dillon P, Gunn RD, Allan G, Nestler JE. Effects of d-chiro-inositol in lean women with the polycystic ovary syndrome. Endocrine practice: official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. Nov-Dec 2002;8(6):417-423.
  87. Lagana AS, Barbaro L, Pizzo A. Evaluation of ovarian function and metabolic factors in women affected by polycystic ovary syndrome after treatment with D-Chiro-Inositol. Archives of gynecology and obstetrics. May 2015;291(5):1181-1186.
  88. La Marca A, Grisendi V, Dondi G, Sighinolfi G, Cianci A. The menstrual cycle regularization following D-chiro-inositol treatment in PCOS women: a retrospective study. Gynecological endocrinology: the official journal of the International Society of Gynecological Endocrinology. Jan 2015;31(1):52-56.
  89. Genazzani AD, Santagni S, Rattighieri E, Chierchia E, Despini G, Marini G, . . . Simoncini T. Modulatory role of D-chiro-inositol (DCI) on LH and insulin secretion in obese PCOS patients. Gynecological endocrinology: the official journal of the International Society of Gynecological Endocrinology. Jun 2014;30(6):438-443.
  90. Isabella R, Raffone E. Does ovary need D-chiro-inositol? Journal of ovarian research. May 15 2012;5(1):14.
  91. Pizzo A, Lagana AS, Barbaro L. Comparison between effects of myo-inositol and D-chiro-inositol on ovarian function and metabolic factors in women with PCOS. Gynecological endocrinology: the official journal of the International Society of Gynecological Endocrinology. Mar 2014;30(3):205-208.
  92. Monastra G, Unfer V, Harrath AH, Bizzarri M. Combining treatment with myo-inositol and D-chiro-inositol (40:1) is effective in restoring ovary function and metabolic balance in PCOS patients. Gynecological endocrinology: the official journal of the International Society of Gynecological Endocrinology. Jan 2017;33(1):1-9.
  93. Benelli E, Del Ghianda S, Di Cosmo C, Tonacchera M. A Combined Therapy with Myo-Inositol and D-Chiro-Inositol Improves Endocrine Parameters and Insulin Resistance in PCOS Young Overweight Women. International journal of endocrinology. 2016;2016:3204083.
  94. Minozzi M, Nordio M, Pajalich R. The Combined therapy myo-inositol plus D-Chiro-inositol, in a physiological ratio, reduces the cardiovascular risk by improving the lipid profile in PCOS patients. European review for medical and pharmacological sciences. Feb 2013;17(4):537-540.
  95. Nordio M, Proietti E. The combined therapy with myo-inositol and D-chiro-inositol reduces the risk of metabolic disease in PCOS overweight patients compared to myo-inositol supplementation alone. European review for medical and pharmacological sciences. May 2012;16(5):575-581.
  96. Colazingari S, Treglia M, Najjar R, Bevilacqua A. The combined therapy myo-inositol plus D-chiro-inositol, rather than D-chiro-inositol, is able to improve IVF outcomes: results from a randomized controlled trial. Archives of gynecology and obstetrics. Dec 2013;288(6):1405-1411.
  97. Kang MJ, Kim JI, Yoon SY, Kim JC, Cha IJ. Pinitol from soybeans reduces postprandial blood glucose in patients with type 2 diabetes mellitus. J Med Food. 2006 Summer; 9(2):182-6.
  98. Bates SH, Jones RB, Bailey CJ. Insulin-like effect of pinitol. Br J Pharmacol. 2000 August;130(8):1944–1948.
  99. Kim MJ, et al. Effect of pinitol on glucose metabolism and adipocytokines in uncontrolled type 2 diabetes. Diabetes Res Clin Prac. 2007;77(Suppl 1):S247-S251.
  100. Kim JI, et al. Effects of pinitol isolated from soybeans on glycaemic control and cardiovascular risk factors in Korean patients with type II diabetes mellitus: a randomized controlled study. Eur Journ Clin Nutr. 2005;59:456–458.
  101. Fulghesu, AM, et al. N-acetyl-cysteine treatment improves insulin sensitivity in women with polycystic ovary syndrome. Fertil Steril. 2002 June; 77(6):1128-1135.
  102. Abu Hashim H, Anwar K, El-Fatah RA. N-acetyl cysteine plus clomiphene citrate versus metformin and clomiphene citrate in treatment of clomiphene-resistant polycystic ovary syndrome: a randomized controlled trial. J Womens Health (Larchmt). 2010 November; 19(11): 2043-8.
  103. Badawy A, State O, Abdelgawad S. N-Acetyl cysteine and clomiphene citrate for induction of ovulation in polycystic ovary syndrome: a cross-over trial. Acta Obstet Gynecol Scand. 2007;86(2):218-22.
  104. Rizk AY, Bedaiwy MA, Al-Inany HG. N-acetyl-cysteine is a novel adjuvant to clomiphene citrate in clomiphene citrate-resistant patients with polycystic ovary syndrome. Fertil Steril. 2005 Feb;83(2):367-70.
  105. Badaway, A, State O, El Gawad S et al. Plasma homocysteine and polycystic ovary syndrome: The missed link. Eur J Obstet Gynecol Reprod Biol. 2007 March; 131(1):68-72.
  106. Rymarz A, Durlik M, Rydzewski. Intravenous administration of N-acetylcysteine reduces plasma total homocysteine levels in renal transplant recipients. Ann Transplant. 2009 Oct-Dec;14(4): 5-9.
  107. Kauffman RP, Tullar PE, Nipp RD, Castracane VD. Serum magnesium concentrations and metabolic variables in polycystic ovary syndrome. Acta Obstet Gynecol Scand. 2011 Jan 4. doi: 10.1111/j.1600-0412.2010.01067.x. [Epub ahead of print]
  108. De Lourdes Lima, M, Cruz T, Pousada JC, Rodrigues LE, Barbosa K, Canguco V. The effect of magnesium supplementation in increasing doses on the control of type 2 diabetes. Diabetes Care 1998 May; 21: 682-86.
  109. Rodriguez-Moran M, Guerrero-Romero F. Oral magnesium supplementation improves insulin sensitivity and metabolic control in type 2 diabetic subjects. Diabetes Care. 2003 April; 26:1147-52.
  110. Mooren FC, Kruger K, Völker S, Golf W, Wadepuhl M, Kraus A. Oral magnesium supplementation reduces insulin resistance in non-diabetic subjects – a double-blind, placebo-controlled, randomized trial. Diabetes, Obesity and Metabolism. 2011 March; 13 (3): 281-84.
  111. Lucidi RS, et al. Effect of chromium supplementation on insulin resistance and ovarian and menstrual cyclicity in women with polycystic ovary syndrome. Fertil Steril. 2005 December; 84(6):1755-7.
  112. Pershadsingh HA. Alpha-lipoic acid: physiologic mechanisms and indications for the treatment of metabolic syndrome. Expert Opin Investig Drugs. 2007 Mar;16(3):291-302.
  113. Masharani U, Gjerde C, Evans JL, Youngren JF, Goldfinel D.Effects of controlled-release alpha lipoic acid in lean, nondiabetic patients with polycystic ovary syndrome. J Diabetes Sci Technol. 2010 Mar 1;4(2):359-64.
  114. Wehr EB et al. Vitamin D-associated polymorphisms are related to insulin resistance and vitamin D deficiency in polycystic ovary syndrome. Eur J Endocrinol. 2011 Mar 9.
  115. Rashidi B et al. The effects of calcium-vitamin D and metformin on polycystic ovary syndrome: a pilot study. Taiwan J Obstet Gynecol. 2009 Jun;48(2):142-7.
  116. Thys-Jacobs S, Donovan D, Papadopoulos A, et al. Vitamin D and calcium dysregulation in the polycystic ovarian syndrome. Steroids.1999 June;64(6):430-5.
  117. Cussons AJ, et al. Omega-3 fatty acid supplementation decreases liver fat content in polycystic ovary syndrome: a randomized controlled trial employing proton magnetic resonance spectroscopy. J Clin Endocrinol Metab. 2009 October; 94(10):3842-8.
  118. Shultz TD, Bonorden WR, R. Seaman MS Wanda. Effect of short-term flaxseed consumption on lignan and sex hormone metabolism in men. Nutr Res. 1991 October;11(10):1089-1100.
  119. Nowak DA, Snyder DC, Brown AJ, Demark-Wahnefried W. The Effect of Flaxseed Supplementation on Hormonal Levels Associated with Polycystic Ovarian Syndrome: A Case Study. Curr Top Nutraceutical Res. 2007;5(4):177–181.
  120. Broadhurst L, Polansky MM, Anderson, RA. Insulin-like biological activity of culinary and medicinal plant aqueous extracts in vitro. J Agric Food Chem. 2000 Mar; 48(3):849–52.
  121. Cao H, Graves DJ, Anderson RA. Cinnamon extract regulates glucose transporter and insulin-signaling gene expression in mouse adipocytes. Phytomedicine. 2010 Nov;17(13):1027-32.
  122. Anderson RA, Broadhurst CL, Polansky MM, et al. Isolation and characterization of polyphenol type-A polymers from cinnamon with insulin-like biological activity. J Agric Food Chem. 2004 Jan 14;52(1):65-70
  123. Khan A et al. Cinnamon Improves Glucose and Lipids in People with Type 2 Diabetes. Diabetes Care. 2003;26:3215-18.
  124. Wang JG, et al. The effect of cinnamon extract on insulin resistance parameters in polycystic ovary syndrome: a pilot study. Fertil Steril. 2007 July;88(1):240-3. Epub 2007 Feb 12.
  125. Armamani D, et al. Licorice reduces serum testosterone in healthy women. Steroids. 2004 October-November;69(11-12):763-766.
  126. Takahashi K, et al. Effect of a traditional herbal medicine (shakuyaku-kanzo-to) on testosterone secretion in patients with polycystic ovary syndrome detected by ultrasound. Nippon Sanka Fujinka Gakkai Zasshi. 1988 June;40(6):789-92.
  127. Takeuchi T, Nishii O, Okamura T, Yaginuma T. Effect of paeoniflorin, glycyrrhizin and glycyrrhetic acid on ovarian androgen production. Am J Chin Med. 1991;19(1):73-8.
  128. Armanini D, et al. Treatment of polycystic ovary syndrome with spironolactone plus licorice. Eur J ObstetGynecolReprod Biol. 2007 Mar;131(1):61-7.
  129. Tsuneki H, Ishizuka M, Terasawa M, et al. Effect of green tea on blood glucose levels and serum proteomic patterns in diabetic (db/db) mice and on glucose metabolism in healthy humans. BMC Pharmacol. 2004 August;26(4):18.
  130. Potenza MA, et al. GCG, a green tea polyphenol, improves endothelial function and insulin sensitivity, reduces blood pressure, and protects against myocardial I/R injury in SHR. Am J Physiol Endocrinol Metab. 2007 May; 292(5):E1378-87. Epub 2007 Jan 16.
  131. Venables MC, et al. Green tea extract ingestion, fat oxidation, and glucose tolerance in healthy humans. Am J ClinNutr. 2008 March; 87(3):778-84.
  132. Wolfram S, Raederstorff D, Preller M, et al. Epigallocatechingallate supplementation alleviates diabetes in rodents. J Nutr. 2006 October;136(10): 2512-8.
  133. Fukino Y, et al. Randomized controlled trial for an effect of green tea-extract powder supplementation on glucose abnormalities. Eur J Clin Nutr. 2008 August; 62(8): 953-60.
  134. Ivanov V, et al. Natural nutrient mixture effectively reduces collagen matrix contraction driven by human uterine smooth muscle cells. J Obstet Gynaecol Res. 2006 February;32(1):23-31.
  135. Dulloo AG, Duret C, Rohrer D, et al. Efficacy of a green tea extract rich in catechin polyphenols and caffeine in increasing 24-h energy expenditure and fat oxidation in humans. Am J Clin Nutr 1999; 70:1040–5.
  136. Grant P. Spearmint herbal tea has significant anti-androgen effects in polycystic ovarian syndrome. A randomized controlled trial. Phytother Res. 2010 Feb; 24(2):186-8.
  137. Prager N, Bicket K, French N, Marovici G. A randomized, double-blind, placebo-controlled trial to determine the effectiveness of botanically derived inhibitors of 5-alpha-reductase in the treatment of androgenetic alopecia. J Alter Complement Med. 2002 April ;8(2):143-152.
;